Nippon India Nifty Pharma ETF

A Other ETF scheme from Nippon India Mutual Fund. Figures below are for the Direct · option not stated plan (ISIN INF204KC1089).

NAV ₹28.8903 on 16 November 2026.

Expense ratio

Total expense ratio 0.23% a year for the Direct · option not stated plan, as AMFI published it on 29 October 2026: base expense ratio 0.18%, brokerage 0.00%, transaction costs 0.00%, statutory levies including GST 0.05%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year25.6%14.8%-7.5%1.261.41
3 years23.1%15.4%-16.6%1.051.05
5 years15.9%15.2%-17.7%0.590.61

Too little NAV history for the 10-year figures.

Not ranked in its category: its category mixes funds too different to rank against one another.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 100.0% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 18.61%
  2. Divi's Laboratories Limited — 12.28%
  3. Laurus Labs Limited — 9.26%
  4. Dr. Reddy's Laboratories Limited — 8.15%
  5. Cipla Limited — 7.67%
  6. Torrent Pharmaceuticals Limited — 6.71%
  7. Lupin Limited — 4.83%
  8. Aurobindo Pharma Limited — 4.59%
  9. Glenmark Pharmaceuticals Limited — 3.42%
  10. Alkem Laboratories Limited — 3.05%

Plans

Other funds in Other ETF

All 232 funds in Other ETF · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.